	US 12,239,631 B2
	Polymorphs of phenyl pyrrole aminoguandium salts
Thomas Boesen, Copenhagen (DK); Thomas Engelbrecht Nordkild Jonassen, Holte (DK); Hayley Ann Reece, Dalkeith (GB); Natalie Louise Kelk, Edinburgh (GB); Alice Jane Turner, Edinburgh (GB); and Ross McLellan, Glasgow (GB)
Assigned to Synact Pharma APS, Holte (DK)
Filed by SYNACT PHARMA APS, Holte (DK)
Filed on May 29, 2024, as Appl. No. 18/676,679.
Application 18/676,679 is a continuation of application No. 17/821,500, filed on Aug. 23, 2022.
Application 17/821,500 is a continuation of application No. PCT/EP2022/066884, filed on Jun. 21, 2022.
Claims priority of application No. 21180702 (EP), filed on Jun. 21, 2021; application No. 21180708 (EP), filed on Jun. 21, 2021; and application No. 21209855 (EP), filed on Nov. 23, 2021.
Prior Publication US 2024/0335423 A1, Oct. 10, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/402 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 31/519 (2006.01); C07D 207/335 (2006.01)

CPC A61K 31/402 (2013.01) [A61K 9/20 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2846 (2013.01); A61K 31/519 (2013.01); C07D 207/335 (2013.01); C07B 2200/13 (2013.01)]

27 Claims

1. A crystalline Form A of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium acetate comprising X-ray lines (2-theta values) in a powder diffraction pattern when measured using Cu K_α radiation at 11.5±0.2, 23.5±0.2, and 27.0±0.2.